In a 70‑year‑old woman with severe rhabdomyolysis, acute kidney injury, heavy proteinuria, hematuria, thrombocytopenia and anemia unresponsive to intravenous fluids and hemodialysis, and negative ANCA, SPEP and urine protein electrophoresis, what is the next appropriate management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 28, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Severe Rhabdomyolysis with Thrombotic Microangiopathy

Proceed immediately to kidney biopsy to establish the diagnosis, while simultaneously testing for ADAMTS13 activity and anti-PF4 antibodies, and discontinue all heparin products if the patient has received any anticoagulation.

Immediate Diagnostic Priorities

This 70-year-old woman presents with a constellation of findings suggesting thrombotic microangiopathy (TMA) superimposed on rhabdomyolysis-induced acute kidney injury. The combination of thrombocytopenia, anemia, heavy proteinuria (>5 grams), hematuria, and refractory acute kidney injury despite dialysis demands urgent TMA evaluation.

Critical Laboratory Tests to Order Now

  • ADAMTS13 activity level and inhibitor titer must be sent urgently to differentiate thrombotic thrombocytopenic purpura (TTP) from other TMAs, as severely deficient activity (<10%) indicates TTP requiring immediate plasma exchange 1, 2, 3
  • Peripheral blood smear for schistocytes is essential, though their absence does not exclude TMA due to low test sensitivity 1
  • Complement testing including C3, C4, and CH50 to evaluate for complement-mediated atypical hemolytic uremic syndrome (aHUS), particularly given the negative ANCA and SPEP 1, 3
  • Anti-PF4 antibodies to exclude heparin-induced thrombocytopenia (HIT), especially if the patient received any heparin during hospitalization or dialysis 4
  • Hemolysis markers including LDH, haptoglobin, indirect bilirubin, and reticulocyte count to confirm microangiopathic hemolytic anemia 1, 2
  • Direct antiglobulin test (Coombs) to exclude immune-mediated hemolysis 2

Kidney Biopsy is Essential

Proceed with kidney biopsy without delay to distinguish between:

  • Acute tubular necrosis from rhabdomyolysis alone
  • Acute tubulointerstitial nephritis (ATIN)
  • Thrombotic microangiopathy affecting the glomeruli
  • Glomerulonephritis (despite negative ANCA, other forms exist)

The biopsy will determine whether the heavy proteinuria and hematuria represent TMA-related glomerular injury versus another concurrent process 4. Early biopsy consideration is recommended as it may negate the need for empiric steroids and clarify the underlying pathology 4.

Empiric Treatment While Awaiting Results

If TTP is Suspected (Based on Clinical Presentation)

Do not wait for ADAMTS13 results if clinical suspicion is high. The decision to initiate plasma exchange should not be delayed, as mortality increases with treatment delay 1, 2, 3.

  • Initiate therapeutic plasma exchange (TPE) immediately at 1-1.5 times plasma volume daily using fresh frozen plasma 2, 3
  • Administer methylprednisolone 1g IV daily for 3 days, starting immediately after the first plasma exchange 1, 2, 3
  • Continue TPE daily until platelet count >150,000/mm³ and LDH normalizes, then taper slowly 2
  • Avoid platelet transfusions unless life-threatening bleeding occurs, as they may worsen thrombosis 2, 3

If Atypical HUS is More Likely

Given the severe renal involvement with heavy proteinuria and the negative ANCA/SPEP, complement-mediated aHUS is a strong consideration, particularly if ADAMTS13 returns >10% 1, 3.

  • Begin eculizumab therapy urgently with dosing: 900 mg IV weekly for 4 doses, then 1,200 mg at week 5, followed by 1,200 mg every 2 weeks 1, 3, 5
  • Administer meningococcal vaccination and initiate long-term penicillin prophylaxis immediately 1, 3
  • In severe renal impairment (creatinine clearance <30 mL/min), eculizumab is the preferred complement inhibitor 5

If HIT is Possible

If the patient received any heparin products (including heparin flushes for dialysis catheters), calculate the 4T score 4:

  • If 4T score ≥6 (high probability): Stop all heparin immediately and switch to argatroban without waiting for anti-PF4 antibody results 4
  • In severe renal impairment (creatinine clearance <30 mL/min), only argatroban can be used among non-heparin anticoagulants 4
  • Initial argatroban dose: 1 mcg/kg/min, reduced to 0.5 mcg/kg/min in critically ill patients 4
  • Danaparoid is contraindicated as first-line treatment in severe renal failure 4

Supportive Care Measures

  • Continue hemodialysis as needed for volume management and uremia 2
  • Transfuse RBCs conservatively, targeting hemoglobin 7-8 g/dL in this stable, non-cardiac patient 1, 2, 3
  • Provide folic acid 1 mg daily supplementation 2
  • Monitor daily: CBC with differential, platelet count, LDH, haptoglobin, and creatinine 1

Critical Pitfalls to Avoid

  • Do not dismiss TMA based on "few" schistocytes alone, as low schistocyte counts can occur in early or evolving TMA 1
  • Do not delay plasma exchange while awaiting ADAMTS13 results if TTP is clinically suspected 1, 2, 3
  • Do not transfuse platelets in suspected TTP/TMA unless life-threatening bleeding is present 2, 3
  • Do not continue heparin if HIT is in the differential diagnosis with intermediate or high 4T score 4
  • Do not assume rhabdomyolysis alone explains all findings—the combination of thrombocytopenia, anemia, and heavy proteinuria demands TMA investigation 1, 6, 7

Algorithm Summary

  1. Send ADAMTS13, complement levels, anti-PF4 antibodies, hemolysis markers, and peripheral smear immediately
  2. Arrange urgent kidney biopsy (within 24-48 hours if possible)
  3. If ADAMTS13 <10%: Start TPE + methylprednisolone
  4. If ADAMTS13 >10% with complement abnormalities: Start eculizumab + vaccination
  5. If heparin exposure + high 4T score: Stop heparin, start argatroban
  6. Continue dialysis and conservative RBC transfusion support
  7. Adjust therapy based on biopsy results and final laboratory confirmation

The persistently elevated CPK despite dialysis is concerning but secondary to the more immediately life-threatening TMA, which requires urgent diagnosis and treatment to prevent irreversible organ damage 1, 6, 7, 8.

References

Guideline

Microangiopathic Hemolytic Anemia (MAHA) with Thrombotic Microangiopathy (TMA)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome Diagnosis and Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Distinguishing and Managing TTP, HUS, and MAHA

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Making the Correct Diagnosis in Thrombotic Microangiopathy: A Narrative Review.

Canadian journal of kidney health and disease, 2021

Research

Diagnosis and treatment of thrombotic microangiopathy.

International journal of laboratory hematology, 2022

Research

Thrombotic microangiopathies: An illustrated review.

Research and practice in thrombosis and haemostasis, 2022

Related Questions

How should I evaluate and manage a patient with new microangiopathic hemolytic anemia (MAHA), thrombocytopenia, elevated lactate dehydrogenase (LDH), low haptoglobin, schistocytes on peripheral smear, and impaired renal function suggestive of thrombotic microangiopathy?
What is the appropriate treatment for Thrombotic Microangiopathy (TMA)?
What is the initial approach to managing a patient with microangiopathic hemolytic anemia and a positive direct Coombs (Direct Antiglobulin) test?
What is the management plan for mild chronic microangiopathy of white matter and the central pons?
How to manage Thrombotic Microangiopathy (TMA) in patients with mechanical heart valves?
Which laboratory tests are indicated for a non‑diabetic patient with persistent proteinuria to assess kidney injury and identify secondary causes?
What does a slightly elevated apolipoprotein B (apoB) indicate regarding cardiovascular risk and management?
What is the cardiovascular risk associated with a fasting apolipoprotein B (apoB) level of 104 mg/dL in an adult without known atherosclerotic cardiovascular disease?
What questions should I ask and how should I assess a 15-year-old for neuroleptic malignant syndrome?
In an adult without known atherosclerotic cardiovascular disease who has an apolipoprotein B of 104 mg/dL and a lipoprotein(a) level below 10 mg/dL, what lipid‑lowering target should be aimed for and what first‑line and subsequent therapies are recommended?
What is the recommended workup for a term newborn male presenting with micropenis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.